| Recent bendamustine treatment before apheresis has a negative impact on outcomes in patients with large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy G Iacoboni, V Navarro, AÁ Martín-López, K Rejeski, M Kwon, KA Jalowiec, ... Journal of Clinical Oncology 42 (2), 205-217, 2024 | 50 | 2024 |
| Impact of cytomegalovirus replication in patients with aggressive B cell lymphoma treated with chimeric antigen receptor T cell therapy E Márquez-Algaba, G Iacoboni, B Pernas, J Esperalba, I Los Arcos, ... Transplantation and Cellular Therapy 28 (12), 851. e1-851. e8, 2022 | 22 | 2022 |
| Salvage treatment with novel agents is preferable to standard chemotherapy in patients with large B-cell lymphoma progressing after chimeric antigen receptor T-cell therapy G Iacoboni, J Iraola-Truchuelo, A Mussetti, P Fernández-Caldas, ... Blood 140 (Supplement 1), 378-380, 2022 | 13 | 2022 |
| Clinical and genomic characterisation of early-onset pancreatic cancer F Castet, C Fabregat-Franco, G Castillo, V Navarro, A Sierra, DA Acosta, ... European Journal of Cancer 194, 113338, 2023 | 9 | 2023 |
| Rethinking placebos: embracing synthetic control arms in clinical trials for rare tumors C Serrano, S Rothschild, G Villacampa, MC Heinrich, S George, JY Blay, ... Nature medicine 29 (11), 2689-2692, 2023 | 8 | 2023 |
| Kinetics of cellular and humoral immunogenicity and effectiveness of SARS‐CoV‐2 booster vaccination in hematologic neoplasms M Jiménez, C Fernández‐Naval, V Navarro, S Novoa, M Martinez‐Gallo, ... American Journal of Hematology 98 (8), 1204-1213, 2023 | 6 | 2023 |
| Clinical and psychological implications of secondary and incidental findings in cancer susceptibility genes after exome sequencing in patients with rare disorders E Carrasco, A López-Fernández, M Codina-Sola, I Valenzuela, ... Journal of Medical Genetics 60 (7), 685-691, 2023 | 4 | 2023 |
| Comprehensive evaluation of surrogate endpoints to predict overall survival in trials with PD1/PD-L1 immune checkpoint inhibitors plus chemotherapy G Villacampa, PC Morgado, V Navarro, C Viaplana, R Dienstmann Cancer Treatment Reviews 116, 102542, 2023 | 4 | 2023 |
| PET‐based radiomics signature can predict durable responses to CAR T‐cell therapy in patients with large B‐cell lymphoma M Ligero, M Simó, C Carpio, G Iacoboni, M Balaguer‐Montero, V Navarro, ... EJHaem 4 (4), 1081-1088, 2023 | 3 | 2023 |
| Impact of prior bendamustine exposure on bispecific antibody treatment outcomes for patients with B-Cell lymphoma G Iacoboni, A Serna, VN Garces, AJ Ubieto, E Valencia, AL Garcia, ... Blood 142, 310, 2023 | 2 | 2023 |
| P1151: BENDAMUSTINE-CONTAINING REGIMENS CAN BE SAFELY USED AS BRIDGING IN LARGE B-CELL LYMPHOMA PATIENTS RECEIVING CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY GII Garcia-Calvo, V Navarro, AAM Lopez, MB Oreiro, K Rejeski, ... HemaSphere 7 (S3), e48751b3, 2023 | 2 | 2023 |
| Bone marrow microenvironment changes in myelodysplastic neoplasms and its relationship with clonal hematopoiesis and disease progression A Molero Yordi, S Peralta, L Gallur, B Tazón, V Navarro Garcés, ... Blood 140 (Supplement 1), 4024-4025, 2022 | 2 | 2022 |
| Resistance Mechanisms Impacting Bispecific Antibody (BsAbs) and Chimeric Antigen Receptor (CAR) T-Cell Therapy Outcomes in Large B Cell Lymphoma (LBCL) Patients J Iraola-Truchuelo, G Iacoboni, L Palomo, VN Garces, J Castellvi, A Mas, ... Blood 142, 1635, 2023 | 1 | 2023 |
| TP53 gene allelic state in myelodysplastic syndromes (MDS) with isolated 5q deletion J Montoro, L Palomo, C Haferlach, P Acha, O Chan, VN Garces, Y Kubota, ... Blood 142, 1001, 2023 | 1 | 2023 |
| Effect on outcomes of toxicity-related dose reduction in TKI monotherapy or TKI-IO combination therapy for advanced renal cell carcinoma. G Nuvola, DH Marmolejo Castañeda, V Mollica, M Santoni, ... Journal of Clinical Oncology 41 (16_suppl), 4528-4528, 2023 | 1 | 2023 |
| Clinical impact of Sars-Cov-2 vaccination in COVID-19 outcomes in patients diagnosed with hematologic malignancies: real-world evidence of two years of pandemic M Jiménez, S Novoa Jáuregui, C Fernández-Naval, M Bosch Schips, ... Blood 140 (Supplement 1), 2628-2630, 2022 | 1 | 2022 |
| Haploidentical donor vs. Mismatch unrelated donor in reduced intensity conditioning transplant: A study from the spanish group of hematopoietic transplant and cell therapy … ML Fox, A Cabirta, A Pérez Martínez, A Esquirol, M Fonseca, ... Blood 140 (Supplement 1), 7631-7633, 2022 | 1 | 2022 |
| Bacterial Cellulose as a UVB Filter to Protect the Skin Microbiota P Alarcón‐Guijo, V Garcés, A González, JM Delgado‐López, R Ullah, ... Macromolecular Bioscience, 2400269, 2024 | | 2024 |
| Efficacy and safety of bendamustine-containing bridging therapy in R/R LBCL patients receiving CD19 CAR T-cells MA Sanchez-Salinas, AÁ Martín-López, M Kwon, G IACOBONI, K Rejeski, ... Wiley, 2024 | | 2024 |
| 121P Early and easy-to-retrieve predictive biomarkers of resistance to immunotherapy in microsatellite instability (MSI)/mismatch repair deficient (dMMR) metastatic colorectal … C Vaghi, FJR Montana, M Mambrilla, VN Garces, R Comas, FS Ballabrera, ... Annals of Oncology 35, S56-S57, 2024 | | 2024 |
